In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...
March 17, 2004 — Long-term use of alendronate continues to be protective against osteoporosis without causing harm, according to the results of a 10-year follow-up study published in the March 18 ...
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-831. Data from the Group Health Atrial ...
Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...
Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...
Please provide your email address to receive an email when new articles are posted on . Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results